Search

Your search keyword '"Falco, Victoria"' showing total 9 results
Start Over Author "Falco, Victoria"
9 results on '"Falco, Victoria"'

1. Vemurafenib and Obinutuzumab as Frontline Therapy for Hairy Cell Leukemia

Author

Park, Jae H., primary, Devlin, Sean, additional, Durham, Benjamin H., additional, Winer, Eric S., additional, Huntington, Scott, additional, von Keudell, Gottfried, additional, Vemuri, Shreya, additional, Shukla, Madhulika, additional, Falco, Victoria, additional, Cuello, Bernadette, additional, Gore, Steven, additional, Stone, Richard, additional, Abdel-Wahab, Omar, additional, and Tallman, Martin S., additional

Published
2023
Full Text
View/download PDF

2. Supplementary Data from Adding Umbralisib and Ublituximab (U2) to Ibrutinib in Patients with CLL: A Phase II Study of an MRD-Driven Approach

Author

Roeker, Lindsey E., primary, Feldman, Tatyana A., primary, Soumerai, Jacob D., primary, Falco, Victoria, primary, Panton, Gail, primary, Dorsey, Colleen, primary, Zelenetz, Andrew D., primary, Falchi, Lorenzo, primary, Park, Jae H., primary, Straus, David J., primary, Pena Velasquez, Camila, primary, Lebowitz, Sonia, primary, Fox, Yehudit, primary, Battiato, Kristen, primary, Laudati, Carissa, primary, Thompson, Meghan C., primary, McCarthy, Elizabeth, primary, Kdiry, Sabrina, primary, Martignetti, Rosalba, primary, Turpuseema, Teja, primary, Purdom, Michelle, primary, Paskalis, Dana, primary, Miskin, Hari P., primary, Sportelli, Peter, primary, Leslie, Lori A., primary, and Mato, Anthony R., primary

Published
2023
Full Text
View/download PDF

3. Data from Adding Umbralisib and Ublituximab (U2) to Ibrutinib in Patients with CLL: A Phase II Study of an MRD-Driven Approach

Author

Roeker, Lindsey E., primary, Feldman, Tatyana A., primary, Soumerai, Jacob D., primary, Falco, Victoria, primary, Panton, Gail, primary, Dorsey, Colleen, primary, Zelenetz, Andrew D., primary, Falchi, Lorenzo, primary, Park, Jae H., primary, Straus, David J., primary, Pena Velasquez, Camila, primary, Lebowitz, Sonia, primary, Fox, Yehudit, primary, Battiato, Kristen, primary, Laudati, Carissa, primary, Thompson, Meghan C., primary, McCarthy, Elizabeth, primary, Kdiry, Sabrina, primary, Martignetti, Rosalba, primary, Turpuseema, Teja, primary, Purdom, Michelle, primary, Paskalis, Dana, primary, Miskin, Hari P., primary, Sportelli, Peter, primary, Leslie, Lori A., primary, and Mato, Anthony R., primary

Published
2023
Full Text
View/download PDF

4. Adding Umbralisib and Ublituximab (U2) to Ibrutinib in Patients with CLL: A Phase 2 Study of an MRD-driven Approach

Author

Roeker, Lindsey E., Feldman, Tatyana A., Soumerai, Jacob D., Falco, Victoria, Panton, Gail, Dorsey, Colleen, Zelenetz, Andrew D., Falchi, Lorenzo, Park, Jae H., Straus, David J., Velasquez, Camila Pena, Lebowitz, Sonia, Fox, Yehudit, Battiato, Kristen, Laudati, Carissa, Thompson, Meghan C., McCarthy, Elizabeth, Kdiry, Sabrina, Martignetti, Rosalba, Turpuseema, Teja, Purdom, Michelle, Paskalis, Dana, Miskin, Hari P., Sportelli, Peter, Leslie, Lori A., and Mato, Anthony R.

Subjects
Neoplasm, Residual, Piperidines, Adenine, Antineoplastic Combined Chemotherapy Protocols, Antibodies, Monoclonal, Humans, Heterocyclic Compounds, 4 or More Rings, Leukemia, Lymphocytic, Chronic, B-Cell, Article
Abstract

Ibrutinib has transformed the management of chronic lymphocytic leukemia (CLL), though its use is limited by toxicity and resistance. In this study, we utilized an "add on" approach for patients who had been treated with ibrutinib in the front-line or relapsed/refractory settings with detectable MRD. Umbralisib and ublituximab (U2) were added on to ibrutinib, patients were treated until achieving undetectable-MRD (U-MRD), and then they entered a period of treatment-free observation (TFO).Patients were eligible if they received ibrutinib in any line of therapy for at least 6 months and had detectable MRD (flow cytometry,1 cell in 10-4 cutoff for U-MRD). U2 was added to ibrutinib, and patients were monitored serially for MRD. Once U-MRD was achieved or a total of 24 cycles were administered, patients entered a period of TFO. The primary study objective was rate of U-MRD. Secondary endpoints included safety and durability of clinical benefit after treatment discontinuation.Twenty-eight patients were enrolled of whom 27 were evaluable for efficacy. Patients received ibrutinib for a median of 21 months (range 7-67) prior to study enrollment. Fourteen patients (52%) have achieved U-MRD per protocol whereas 78% had at least one U-MRD evaluation. Seventeen patients (63%) have entered TFO after a median of 6.4 months on triplet therapy. Progression-free survival at 12 months was estimated at 95%. Grade ≥3 adverse events were hypertension 7%, diarrhea 4%, and increased ALT/AST 4%.This triplet approach utilizes the addition of U2 to ibrutinib as an MRD-driven time-limited therapy. This therapy was well tolerated and effective. TFO following this therapy appears durable in ongoing follow-up.

Published
2022

5. Adding Umbralisib and Ublituximab (U2) to Ibrutinib in Patients with CLL: A Phase II Study of an MRD-Driven Approach

Author

Roeker, Lindsey E., primary, Feldman, Tatyana A., additional, Soumerai, Jacob D., additional, Falco, Victoria, additional, Panton, Gail, additional, Dorsey, Colleen, additional, Zelenetz, Andrew D., additional, Falchi, Lorenzo, additional, Park, Jae H., additional, Straus, David J., additional, Pena Velasquez, Camila, additional, Lebowitz, Sonia, additional, Fox, Yehudit, additional, Battiato, Kristen, additional, Laudati, Carissa, additional, Thompson, Meghan C., additional, McCarthy, Elizabeth, additional, Kdiry, Sabrina, additional, Martignetti, Rosalba, additional, Turpuseema, Teja, additional, Purdom, Michelle, additional, Paskalis, Dana, additional, Miskin, Hari P., additional, Sportelli, Peter, additional, Leslie, Lori A., additional, and Mato, Anthony R., additional

Published
2022
Full Text
View/download PDF

6. First Line Chemo-Free Therapy with the BRAF Inhibitor Vemurafenib Combined with Obinutuzumab Is Effective in Patients with Hcl

Author

Park, Jae H, primary, Winer, Eric S., additional, Huntington, Scott F., additional, von Keudell, Gottfried, additional, Vemuri, Shreya, additional, Shukla, Madhulika, additional, Kinoshita, Julie C, additional, Falco, Victoria, additional, Gore, Steven D., additional, Stone, Richard M., additional, Abdel-Wahab, Omar, additional, and Tallman, Martin S., additional

Published
2021
Full Text
View/download PDF

7. A Phase 2 Study Evaluating the Addition of Ublituximab and Umbralisib (U2) to Ibrutinib in Patients with Chronic Lymphocytic Leukemia (CLL): A Minimal Residual Disease (MRD)-Driven, Time-Limited Approach

Author

Roeker, Lindsey E., primary, Leslie, Lori A., additional, Soumerai, Jake D., additional, Falco, Victoria, additional, Panton, Gail, additional, Zelenetz, Andrew D., additional, Falchi, Lorenzo, additional, Park, Jae H, additional, Pena-Velasquez, Camila, additional, Lebowitz, Sonia, additional, Battiato, Kristen, additional, Laudati, Carissa, additional, Thompson, Meghan C., additional, Straus, David J., additional, Fox, Yehudit, additional, McCarthy, Elizabeth, additional, Kdiry, Sabrina, additional, Martignetti, Rosalba, additional, Miskin, Hari P., additional, Sportelli, Peter, additional, and Mato, Anthony R., additional

Published
2021
Full Text
View/download PDF

8. A Phase 2 Study of Minimal Residual Disease (MRD)-Adapted Front Line Venetoclax and Obinutuzumab in Fit Patients with Chronic Lymphocytic Leukemia (CLL): Effect of Obinutuzumab on Tumor Lysis Syndrome (TLS) Risk and Safety of Outpatient Venetoclax Dose Escalation

Author

Roeker, Lindsey E., Zelenetz, Andrew D., Park, Jae H., Derkach, Andriy, Geyer, Mark Blaine, Islam, Prioty, Falchi, Lorenzo, Palomba, Maria Lia, Kumar, Anita, Salles, Gilles, Lue, Jennifer Kimberly, Goldberg, Aaron D., Fakhri, Bita, Coombs, Catherine C., Falco, Victoria, Panton, Gail, Tyznar, Dianna, Soni, Dhara, Nogan, Lauren, Lebowitz, Sonia, Blesie, Katherine, Shah, Monica, Court, Sarah, Jensen, Christopher E., Mato, Anthony R., and Thompson, Meghan C.

Published
2023
Full Text
View/download PDF

9. A Once Daily, Oral, Triple Combination of BTK Inhibitor, mTOR Inhibitor and IMiD for Treatment of Relapsed/Refractory Richter's Transformation and De Novo Diffuse Large B-Cell Lymphoma

Author

Mato, Anthony R., primary, Schuster, Stephen J., additional, Foss, Francine M., additional, Isufi, Iris, additional, Kothari, Shalin K., additional, Ding, Wei, additional, Brander, Danielle M., additional, Sitlinger, Andrea, additional, Rosenthal, Allison C., additional, Leis, Jose F., additional, Tun, Han W., additional, Kennard, Kaitlin, additional, Nelson, Allison R., additional, Falco, Victoria, additional, Komari, Celina J., additional, Koehler, Amber B., additional, Stowe, Rachel, additional, He, Wei, additional, Kearney, Albert, additional, Gui, Min, additional, McKinlay, Tim, additional, Roeker, Lindsey E, additional, Thompson, Meghan C., additional, and Huntington, Scott F., additional

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results